Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors

被引:0
作者
Kayondo, Jonathan K. [1 ]
Ndembi, Nicaise [2 ]
Parry, Chris M. [2 ]
Cane, Patricia A. [3 ]
Hue, Stephane [4 ]
Goodall, Ruth [5 ]
Dunn, David T. [5 ]
Kaleebu, Pontiano [1 ,2 ]
Pillay, Deenan [4 ]
Mbisa, Jean L. [3 ]
机构
[1] Uganda Virus Res Inst, Uganda Res Unit AIDS, Entebbe, Uganda
[2] UVRI, MRC, Uganda Res Unit AIDS, Entebbe, Uganda
[3] Publ Hlth England, Virus Reference Dept, London, England
[4] UCL, Dept Infect & Immun, London, England
[5] UCL, MRC, Clin Trials Unit, London, England
基金
英国惠康基金;
关键词
DRUG-RESISTANCE; HIV; INTERRUPTION; INFECTION;
D O I
10.1089/aid.2015.0035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Structured treatment interruption (STI) has been trialed as an alternative to lifelong antiretroviral therapy (ART). We retrospectively performed single genome sequencing of the HIV-1 pol region from three patients representing different scenarios. They were either failing on continuous therapy (CT-F), failing STI (STI-F), or suppressing on STI (STI-S). Over 460 genomes were generated from three to five different time points over a 2-year period. We found multiple-linked-resistant mutations in both treatment failures. However, the CT-F patient showed a stepwise accumulation of diverse, linked mutations whereas the STI-F patient had lineage turnover between treatment periods with recirculation of wild-type and resistant variants from reservoirs. The STI-F patient showed a 7-fold increase in the third codon position substitution rate relative to the first and second positions compared to a 2-fold increase for CT-F and increased purifying selection in the pol gene (62 vs. 22 sites, respectively). An understanding of intrapatient viral dynamics could guide the future direction of treatment interruption strategies.
引用
收藏
页码:749 / 756
页数:8
相关论文
共 50 条
  • [21] Unusual codon 69 insertions:: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility
    Bulgheroni, E
    Croce, F
    Citterio, P
    Viganò, O
    Visonà, R
    Sala, E
    Galli, M
    Rusconi, S
    JOURNAL OF CLINICAL VIROLOGY, 2004, 29 (01) : 27 - 32
  • [22] Differential Evolution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes Between HAART-Failing and Naive-Treated Individuals
    Varella, Rafael B.
    Schrago, Carlos G.
    Zalis, Mariano G.
    CURRENT HIV RESEARCH, 2009, 7 (06) : 601 - 605
  • [23] Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles
    Shiang, Yen-Chun
    Ou, Chung-Mao
    Chen, Shih-Ju
    Ou, Ting-Yu
    Lin, Han-Jia
    Huang, Chih-Ching
    Chang, Huan-Tsung
    NANOSCALE, 2013, 5 (07) : 2756 - 2764
  • [24] Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors
    Peduzzi, C
    Pierotti, P
    Venturi, G
    Romano, L
    Mazzotta, F
    Zazzi, M
    JOURNAL OF CLINICAL VIROLOGY, 2002, 25 (01) : 57 - 62
  • [25] Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients
    Dunn, Linda L.
    Boyer, Paul L.
    McWilliams, Mary Jane
    Smith, Steven J.
    Hughes, Stephen H.
    VIROLOGY, 2015, 484 : 127 - 135
  • [26] In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins
    Sun, RWY
    Yu, WY
    Sun, HZ
    Che, CM
    CHEMBIOCHEM, 2004, 5 (09) : 1293 - 1298
  • [27] The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase
    Gao, HQ
    Boyer, PL
    Sarafianos, SG
    Arnold, E
    Hughes, SH
    JOURNAL OF MOLECULAR BIOLOGY, 2000, 300 (02) : 403 - 418
  • [28] Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways
    Van Laethem, Kristel
    Pannecouque, Christophe
    Vandamme, Anne-Mieke
    INFECTION GENETICS AND EVOLUTION, 2007, 7 (05) : 600 - 603
  • [29] Structural Modulation Study of Inhibitory Compounds for Ribonuclease H Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase
    Yanagita, Hiroshi
    Fudo, Satoshi
    Urano, Emiko
    Ichikawa, Reiko
    Ogata, Masakazu
    Yokota, Mizuho
    Murakami, Tsutomu
    Wu, Honggui
    Chiba, Joe
    Komano, Jun
    Hoshino, Tyuji
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2012, 60 (06) : 764 - 771
  • [30] Progress of Bis(heteroaryl)piperazines (BHAPs) as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) against Human Immunodeficiency Virus Type 1 (HIV-1)
    Xu, Hui
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (01) : 62 - 72